Search Results

Welcome back to your weekly GPCR quest!

had significant antagonistic effects on PxOctβ3, whereas yohimbine, phentolamine, and chlorpromazine lacked

Now back in Europe, all she can think about is next year’s date, in Dublin, where she is sure she will

diseases, but few therapies have been directed against GPCRs in the field of cancer, partly because of the lack

Effective methods to treat preeclampsia are lacking, and termination of pregnancy remains the only curative

The clarity that was desperately lacking. The unnecessary friction that slowed everything down.

physiological and disease functions, yet knowledge of their role in colon cancer stem cell maintenance is still lacking

Terry Kenakin will return with two back-to-back classes.

in endothelial cells, which was evidenced by the attenuation of organ fibrosis in mice specifically lacking

Currently-approved treatments have improved patient outcomes, but therapies to stop or reverse HF are lacking

Who I Work With ✅ Biotech Teams  – Especially those lacking in-house GPCR leads or overwhelmed by CRO

extracellular N-termini by 31 amino acids, but detailed insights into their functional differences are lacking

The panels are packed. Everyone’s rushing from one talk to the next. But the truth?

The Era of Cold Fingers and Patience Back then, GPCR signaling experiments weren’t elegant; they were

Many GPCR scientists trace their origin story back to a single unexpected spark. Not a grand plan.

The lack of transparency surrounding its operations and usage constraints restricts extensive academic

Welcome back GPCR Fans, Clean data can still mislead if the underlying assumptions aren’t tested.

quantification of SST2/SST5 dimerization in rat GH3 as well as in human melanoma cells either expressing (A7) or lacking

UNC and Terry's Corner We'll continue to update this section as new videos are released — so check back

or pharmacological activation of endogenous Ca2+ signaling transducers; however, such approaches can lack

Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already

stall not because the target is wrong—but because the chemical matter  interacting with that target lacks

And once you see it, you’ll never go back.

And once you make that shift, you’ll never go back.

It was mostly just because, I need to be back in the lab.”

Using CRISPR-Cas9 knockout HEK cells lacking Gs proteins, a study by Stallaert et al. in 2017 showed

Jack Antel to its clinical advisory board Crinetics Pharmaceuticals First Quarter 2023 Earnings: Revenues

Premium members can always go back and watch the recorded talks at any time.

With over 21,000 views  and 7,785 downloads  from Volume I, the Signal Transduction  Research Topic is back

Our website is updated as we confirm speakers so please check back often.